The Best Dividend Stocks to Buy With $5,000 in November

The article identifies AbbVie, Johnson & Johnson and Medtronic as long-term dividend-stock buying opportunities amid competition from AI stocks and a 4.9% 10-year Treasury yield. Their forward dividend yields are 2.4%, 2% and 3%, respectively; analysts expect adjusted EPS growth of 22% and 9% CAGR for AbbVie and J&J from 2025–2028, and 8% for Medtronic from fiscal 2026–2029. Medtronic has returned negative 5% over five years, but the article points to improving earnings and a 15-times-forward-earnings valuation; AbbVie and J&J trade at 18 and 25 times next year's earnings.

Analysis

The key issue is not whether these companies can sustain dividends; it is whether earnings growth can outrun the opportunity cost of safer yields. With Treasury yields materially above the cited equity yields, payout records alone are unlikely to drive near-term multiple expansion. A sustained decline in long rates would help all three; another leg up in yields could pressure their valuations even if operating results hold up.

The strongest fundamental asymmetry is AbbVie: if Skyrizi and Rinvoq replace Humira cash flows as expected, earnings growth can support both the dividend and valuation. But the cited growth outlook is an analyst forecast, not a de-risked outcome; execution or acquisition-integration disappointments could quickly undermine it. Johnson & Johnson offers lower growth against a higher earnings multiple, so its defensive reputation may not compensate if investors favor earnings momentum over stability.

Medtronic’s recovery is a potential re-rating story, but less certain: better costs and cardiovascular growth need to translate into sustained organic growth, while the diabetes separation changes the business and its comparison base. The spinout also makes MiniMed a distinct exposure—not a Medtronic segment—so assess each company’s results separately. Over 1–3 months, rates and guidance likely dominate; over 6–18 months, drug replacement and device execution matter more. The contrarian risk is buying “yield” as a bond substitute when these remain equity-duration assets.

Key Decisions for Investors

• Avoid a basket purchase based on dividend streaks alone. For income exposure, compare each stock’s earnings and dividend growth with the prevailing Treasury yield; defer adding if long rates are rising and estimate revisions are weakening.
• Prefer ABBV over JNJ on relative fundamentals, but only as a measured relative-value position after confirming Skyrizi/Rinvoq growth and the next guidance update. Falsify the thesis on material growth or earnings-estimate cuts, or evidence that Humira replacement is stalling.
• Keep MDT on a catalyst watch rather than treating its lower multiple as proof of cheapness. Revisit after results show sustained organic growth and margin progress; reassess if procedure demand, quality issues, or post-separation performance disappoint.
• Monitor the 10-year yield and rate expectations as near-term risk controls: a renewed rise would challenge dividend-stock multiples, while a durable decline could ease that headwind. Do not assume dividend income offsets capital losses.